Quince Therapeutics, Inc. (NASDAQ:QNCX) Given Consensus Recommendation of “Buy” by Brokerages

Quince Therapeutics, Inc. (NASDAQ:QNCX) has earned a consensus recommendation of “Buy” from the six research firms that are currently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $9.50.

QNCX has been the subject of a number of analyst reports. Brookline Capital Management initiated coverage on Quince Therapeutics in a research report on Wednesday, December 18th. They issued a “buy” rating and a $9.00 price target for the company. RODMAN&RENSHAW upgraded Quince Therapeutics to a “strong-buy” rating in a research report on Tuesday, October 29th. Rodman & Renshaw initiated coverage on Quince Therapeutics in a research report on Tuesday, October 29th. They issued a “buy” rating and a $11.00 price target for the company. D. Boral Capital restated a “buy” rating and issued a $12.00 price target on shares of Quince Therapeutics in a research report on Wednesday, February 5th. Finally, Maxim Group assumed coverage on Quince Therapeutics in a research report on Thursday, November 7th. They issued a “buy” rating and a $6.00 price target for the company.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in QNCX. Shay Capital LLC grew its position in Quince Therapeutics by 60.8% in the fourth quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock worth $518,000 after acquiring an additional 104,616 shares during the period. Scharf Investments LLC acquired a new position in Quince Therapeutics during the fourth quarter worth $170,000. Geode Capital Management LLC lifted its stake in Quince Therapeutics by 24.2% during the third quarter. Geode Capital Management LLC now owns 339,125 shares of the company’s stock worth $263,000 after purchasing an additional 66,170 shares in the last quarter. Two Sigma Investments LP acquired a new position in Quince Therapeutics during the fourth quarter worth $57,000. Finally, Virtu Financial LLC acquired a new position in Quince Therapeutics during the fourth quarter worth $55,000. 30.75% of the stock is currently owned by hedge funds and other institutional investors.

Quince Therapeutics Price Performance

NASDAQ:QNCX opened at $1.45 on Friday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. The stock has a 50 day moving average of $1.68 and a two-hundred day moving average of $1.31. The firm has a market cap of $63.80 million, a P/E ratio of -1.17 and a beta of 0.61. Quince Therapeutics has a 12 month low of $0.51 and a 12 month high of $2.45.

About Quince Therapeutics

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.